

ODAC

JANUARY 12-15, 2023

JW MARRIOTT ORLANDO GRANDE LAKES
ORLANDO, FLORIDA

TABLE OF CONTENTS

FACULTY AND ADVISORS	2
IMPORTANT SHOW INFORMATION	3
MUST-ATTEND EVENTS	4
EXHIBIT HALL ACTIVITIES	5
EXHIBIT FLOOR PLAN	6
AGENDA.....	7
ACCREDITATION INFORMATION	12

HUMANAE: THE BEAUTY OF BEING HUMAN

Angelica Dass Keynote Address
Friday, 6:30 – 7:00 PM

WELCOME RECEPTION IN EXHIBIT HALL

Friday, 7:00 – 8:30 PM

SESSION HANDOUTS AND ODAC EVENT APP

The ODAC event app is your comprehensive resource to view and save session handouts, enter contests, complete surveys, and access other important conference information.

WORKSHOPS

No RSVP required, however, seats are limited and available first-come first-served. Please plan to arrive early

FOLLOW US  @ODAC_DERM  @ODACDERM  @ODAC_DERM #ODAC2023

ORLANDODERM.ORG

A product of
 sanovaworks

JOINTLY PROVIDED BY



Postgraduate Institute
for Medicine



WHERE DERMATOLOGY EXPERTS CONVERGE

A MESSAGE FROM OUR FACULTY

Dear Colleagues,

On behalf of our chairs and faculty, we welcome you to the 21st annual ODAC Dermatology, Aesthetic and Surgical Conference. ODAC is the premier annual CME conference expertly curated to provide comprehensive, annual updates and fresh pearls in medical, aesthetic and surgical dermatology.

Over the next four days, you will join the ranks of the foremost pioneers in dermatology to share progressive medical, surgical and cosmetic insights, in a highly interactive format.

- Discuss the next generation of diagnostic approaches and evidence-based treatments
- Observe cutting-edge procedures and techniques with live demonstrations of novel products and emerging technologies
- Review clinical trial results and discuss case studies in both large and small group settings
- Cultivate relationships with colleagues and leaders actively shaping the future of dermatology

ODAC recognizes that you hold the vision, highly specialized expertise, and unique training that drives dermatology. We are happy you are here and thank each of you for being part of this exclusive event.

2023 ESTEEMED FACULTY



Perry Robins, MD
Conference Chair Emeritus



James Spencer, MS
Conference Chair Emeritus



Joel L. Cohen, MD
Co-Chair



Adam Friedman, MD
Co-Chair



Susan H. Weinkle, MD
Co-Chair



Omar Qutub, MD
Director of Equity,
Diversity, and Inclusion

PRESENTING FACULTY

Blair Allais, MD
Mathew Avram, MD
Joel Cohen, MD
DiAnne Davis, MD
Nada Elbuluk, MD
John Fezza, MD
Timothy Flynn, MD
Adam Friedman, MD
George Han, MD
C. William Hanke, MD
Molly Hinshaw, MD
Omar Ibrahim, MD
Terrence Keaney, MD
Leon Kircik, MD
A. Yasmine Kirkorian, MD
Shawn Kwatra, MD
Kalyani Marathe, MD

Kavita Mariwalla, MD
Hadar Lev-Tov, MD
Iltefat Hamzavi, MD
John Harris, MD
Amy McMichael, MD
Arisa Ortiz, MD
David Ozog, MD
Vishal A. Patel, MD
Omar Qutub, MD
Nazanin Saedi, MD
Karl Saardi, MD
Robyn Siperstein, MD
James Spencer, MD
Jennifer Stein, MD
Susan Weinkle, MD

CHECK THE EVENT APP FOR FACULTY BIOS AND UPDATES.

**WE THANK THE FOLLOWING FORMER AND CURRENT
DERM IN-REVIEW ADVISORY COUNCIL MEMBERS FOR THEIR
CONTRIBUTION TO ODAC 2023:**

Mojgan Hosseinipour, DO
Peer Reviewer

Nishad Sathe, MD
Onsite Correspondent

Shanthi Narla, MD
Onsite Correspondent

Matthew Willett, MD
Peer Reviewer

VISIT BOOTH #202 FOR
LIFE-CHANGING SOLUTIONS
FOR YOUR PATIENTS



LIFE-CHANGING DERMATOLOGY POWERED BY MICROBIOME SCIENCE

At La Roche-Posay, we advance skin microbiome science to promote skin health for all. Partnering with dermatologists, we provide life-changing dermatological solutions.

IMPORTANT SHOW INFORMATION

COMPLIMENTARY WIFI

WiFi is available throughout the event space.

Network Name: **ODAC 2023**

Access Code: **dupilumab**

The access code is case sensitive.

SUPPORTED BY **sanofi** | **REGENERON**

SESSION HANDOUTS AND EVENT APP

Utilize the ODAC event app to view and save session handouts, take notes, and access important conference information. Instructions for downloading the app can be found on page 5.

ONSITE CONTESTS

ODAC is about professional development, but we also love to have fun! ODAC's official media partner, the *Journal of Drugs in Dermatology* (JDD), is sharing in the fun with their ODAC giveaways.

PRIZES

- \$500 AMEX Gift Card
- Apple AirPods
- ODAC 2024 Registration

HOW TO PLAY

- Access the ODAC game in the ODAC Event App
- Unlock passcodes by completing challenges
- Enter passcodes to earn points
- Complete as many challenges as you can and climb to the top of the leaderboard!

LIST OF CURRENT "CHALLENGES"

- Posting on social media with #ODAC2023 (Post must be set as public)
- Sharing or commenting on ODAC social media posts
- ODAC 2024 onsite registration
- Skin of Color Update 2023 onsite registration
- ODAC survey completion
- Visit each sponsor booth and get a code from the onsite representative
- Post a comment or photo on the "Event Feed" in the Event App

Winners will be announced on ODAC's social media channels and through the event app. There are no limits to the number of entries you may earn.

FOLLOW ODAC FOR LIVE UPDATES

 @ODAC_DERM
  @ODACDERM
  @ODAC_DERM

HOW TO CLAIM CME

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

To obtain your CE certificate, please follow the steps below at the conclusion of the activity:

1. Go to <https://www.cmeuniversity.com>
2. Login or Create a New Account (will take less than 1 minute)
 - If you receive a message when creating a new account that "the email you entered is already in use", please click the Forgot my Password link to have your Username and Password sent to you via email. Emails from the system usually go straight to spam.
3. After logging in, you may be asked to verify/update your profile information; after doing so, click Save at the bottom of the page
4. Once you're logged in, search for the course ID 17508 in the box at the top of the page labeled "Find Post Test/Evaluation by Course".
5. Click on the title.
6. Choose the type of credit you desire
7. Complete the online Evaluation
8. Receive an immediate CE Certificate to download and/or print for your files
9. If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

POSTER SESSION

Posters are available in the foyer outside Exhibit Hall.

SUPPORTED BY 

ADA STATEMENT

ADA accommodations will be made in accordance with the law. If you require ADA accommodations, please indicate what your needs are at the time of registration. We cannot ensure the availability of appropriate accommodations without prior notification.

CAMERA/VIDEO RECORDING POLICY

Use of cameras/photography, camera phones and video equipment is strictly prohibited in all educational sessions.

GUEST PASS

A Guest Pass allows access to the exhibit hall networking sessions only. To upgrade your pass for admittance to educational sessions, please visit the registration desk.

For general conference information, please visit the registration desk.

Workshops fill quickly and are available on a first come, first serve basis. Please plan to arrive early.

SAVE THE DATE – ODAC 2024

JANUARY 11–14, 2024

SIGNIA BY HILTON ORLANDO BONNET CREEK, ORLANDO, FLORIDA

REGISTER THIS WEEKEND TO

RECEIVE 30% OFF!

USE CODE **ODACDERM** AT **ORLANDODERM.ORG**.

ODAC HOT SESSIONS*

THURSDAY

▶ 6:00 – 7:00 PM | DINNER SYMPOSIUM

Top Cosmeceutical Picks from La Roche-Posay for Restorative and Preventative Aging

Supported by La Roche-Posay
Faculty: Timothy C. Flynn, MD Nada Elbuluk, MD
Location: Mediterranean 6

PRODUCT DISTRIBUTION

FRIDAY

▶ 8:00 – 9:00 AM | BREAKFAST WORKSHOPS

Alopecia Areata: What You Need to Know

Supported by Pfizer
Faculty: Amy McMichael, MD
Location: Mediterranean 6

VTAMA® (tapinarof) cream, 1% as a Novel Topical Therapy for Adult Plaque Psoriasis

Supported by Dermavant
Faculty: George Han, MD
Location: Mediterranean 7

▶ 12:30 – 1:30 PM | LUNCH WORKSHOPS

A Treatment Option for Adults with Prurigo Nodularis

Supported by Sanofi and Regeneron Pharmaceuticals, Inc.
Faculty: Adam Friedman, MD
Location: Mediterranean 6

Mild to Moderate Atopic Dermatitis: Burden of Disease and a Topical Pathway for JAK Inhibition

Supported by Incyte
Faculty: Leon Kircik, MD
Location: Mediterranean 7

▶ 6:30 – 7:00 PM | KEYNOTE ADDRESS

Humanae: The Beauty of Being Human

Faculty: Angélica Dass
Location: General Session Room

▶ 7:00 – 8:30 PM | WELCOME RECEPTION

Location: Exhibit Hall

SATURDAY

▶ 7:20 – 8:20 AM | BREAKFAST WORKSHOP

WINLEVI® (clascoterone) cream 1%, First-in-Class Topical Androgen Receptor Inhibitor for the Treatment of Acne Vulgaris

Faculty: Leon Kircik, MD
Location: Mediterranean 6

▶ 12:30 – 1:30 PM | LUNCH WORKSHOPS

Insights Into a New Oral Treatment Option for Adults With Moderate-to-Severe Plaque Psoriasis

Supported by Bristol Myers Squibb
Faculty: Adam Friedman, MD
Location: Mediterranean 6

A Targeted Approach to the Treatment of Nonsegmental Vitiligo

Supported by Incyte
Faculty: Heather Woolery-Lloyd, MD
Location: Mediterranean 7

▶ 3:30 – 4:30 PM | AFTERNOON WORKSHOP

AART of GAIN

Supported by Galderma
Faculty: Joel Cohen, MD, Robyn Siperstein, MD
Location: Mediterranean 6

LIVE DEMONSTRATION

▶ 5:30 – 6:30 PM | DINNER SYMPOSIUM

Resident Dinner Symposium: Make SILIQ Your Bio-Logical Next Step

Supported by Ortho Dermatologics
Faculty: George Han, MD
Location: Mediterranean 6

RESIDENT TRACK

Join Pfizer: Learn About an Oral RX Treatment for Moderate-to-Severe Atopic Dermatitis

Supported by Pfizer
Faculty: Zakiya P. Rice, MD
Location: Mediterranean 7

SUNDAY

▶ 7:20 – 8:20 AM | BREAKFAST WORKSHOP

SP Dynamis, The Best Multi-Use Energy Device

Supported by Fotona
Faculty: DiAnne Davis, MD
Location: Mediterranean 6

LIVE DEMONSTRATION

#ODAC2023

THE OFFICIAL HASHTAG
OF **ODAC 2023**

*Non-CE

SESSION HANDOUTS AND EVENT APP

You can access the ODAC 2023 event via a mobile app and web app. The web app will provide you with a more detailed, full-screen experience, while the mobile app is great for tablets and phones. We suggest using the website to join the event for the first time.

WEB APP

1. Go to tiny.cc/ODAC23 or scan the **QR CODE**
2. Click the button that says **ACCESS ON THE WEB**
3. Enter the email you registered for the conference with.
 - **IMPORTANT:** Only sign in using your email, do not sign in using Webex, LinkedIn, Google, or Apple.
4. Set a new password OR enter your password from a previous ODAC or SOCU event.
 - If you do not remember your previous password, click the "Forgot Your Password?" link and you will receive a password reset email.
5. Complete your profile. Your profile is your tool to network with faculty and fellow attendees. It is very important that your profile is complete to enhance your virtual experience!
6. Tune in to sessions, browse presentations, speakers, sponsors and more!



MOBILE APP

1. Scan the **QR CODE** or navigate to your device's app store (Apple App Store or Google Play).
2. Search for and download the **WEBEX EVENT APP**.
3. Enter the email you used when you logged in to the Event Web App above.
4. Enter your password.
5. Click the **ODAC 2023** event to enter.
6. Tune in to sessions, browse presentations, speakers, sponsors and more!

In some cases, patient images have been removed from handouts due to HIPAA privacy rule and/or copyright restrictions. In some cases, handouts may be slightly different than the PPTs shown during sessions.

Only handouts that have been approved by faculty for distribution will be available for viewing/downloading.

WIN PRIZES!

Brought to you by the
Journal of Drugs in Dermatology

- \$500 AMEX GIFT CARD
- APPLE AIRPODS
- ODAC 2024 REGISTRATION

HOW TO PLAY

Access the ODAC game in the ODAC Event App.

- Unlock passcodes by completing challenges
- Enter passcodes to earn points
- Complete as many challenges as you can and climb to the top of the leaderboard!

List of Current "Challenges"

- Posting on social media with #ODAC2023 (Post must be set as public)
- Sharing or commenting on ODAC social media posts
- ODAC 2024 onsite registration
- Skin of Color Update 2023 onsite registration
- ODAC survey completion
- Visit each sponsor booth and get a code from the onsite representative
- Post a comment or photo on the "Event Feed" in the Event App

TAKE OUR SURVEYS AND WIN \$\$\$

Access surveys on the event app and be entered to win \$500, Apple AirPods or an ODAC 2024 Registration!

SAVE THE DATE – ODAC 2024

JANUARY 11–14, 2024

SIGNIA BY HILTON ORLANDO BONNET CREEK, ORLANDO, FLORIDA

REGISTER THIS WEEKEND TO
RECEIVE 30% OFF!

USE CODE ODACDERM AT ORLANDODERM.ORG.

EXHIBIT HALL




EXHIBIT HALL HOURS

FRIDAY, JANUARY 13

12:30 PM – 8:30 PM

- ▶ 12:30 – 1:45 PM Lunch
- ▶ 3:45 – 4:30 PM Refreshment Break and Coffee Chat with Faculty
- ▶ 7:00 – 8:30 PM Welcome Reception

SATURDAY, JANUARY 14

9:00 AM – 4:30 PM

- ▶ 10:30 – 11:00 AM Refreshment Break and Coffee Chat with Faculty
- ▶ 12:30 – 1:30 PM Lunch
- ▶ 3:30 – 4:30 PM Refreshment Break

SUNDAY, JANUARY 15

9:00 AM – 1:45 PM

- ▶ 10:30 – 11:00 AM Refreshment Break and Coffee Chat with Faculty
- ▶ 12:30 – 1:45 PM Lunch

EXHIBITORS

Acquire Tax Credits	207	Forefront Dermatology	411	Pfizer (Commercial)	209
Advanced Dermatology and Cosmetic Surgery	405	Fotona, LLC.	302	Pfizer (Medical)	309
Aerolase	311	Galderma	407/409	Practice Real Estate Group	205
Allergan Aesthetics	305	ID Medical Devices LLC	408	Proctor & Gamble	412
Almirall	304	Incyte	308/310	Sanofi and Regeneron Pharmaceuticals Inc.	208/210
Amgen	401	Integrated Dermatology	313	Cyspera® by Scientis	414
Beiersdorf	112	Janssen Biotech, Inc.	306	Sonic Healthcare USA, Dermatopathology	211/213
Biofrontera Inc.	410	Johnson & Johnson Consumer Inc.	307	STRATA Skin Sciences	312
Bristol Myers Squibb	301/303	La Roche-Posay	202/204	SUN Pharma	212/214
Castle Biosciences	416	Leo Pharma Inc.	402	UCB	403
Clarius Mobile Health	114	ModMed	314	Topicals	406
Dermatology Authority	203	Novartis Pharmaceuticals	418	Weave	201
Dermavant Sciences, Inc.	102/104	Nutrafol	110	Zero Gravity Skin	206
EPI Health	403	OBAGI	108		
Ferndale Healthcare, Inc.	106	Ortho Dermatologics	404		

DUPIXENT[®]
(dupilumab)



**SEE WHAT'S
ACHIEVABLE**

LEARN MORE

DupixentHCP.com

sanofi | **REGENERON[®]**

© 2022 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT[®] is a registered trademark of Sanofi Biotechnology.

11/2022 DUP.22.10.0210

AGENDA | THURSDAY, JANUARY 12, 2023

1:30 – 3:00 PM | GENERAL SESSION I

“Too Much, Too Little, or None At All: A Deeper Dive into Disorders of Hyperpigmentation, Hypopigmentation, and Depigmentation”

Welcome and Introductions	Adam Friedman, MD	General Session Room
Disorders of Hyperpigmentation	Nada Elbuluk, MD	General Session Room
Disorders of Hypopigmentation	Iltefat Hamzavi, MD	General Session Room
Disorders of Depigmentation	John Harris, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

3:00 – 4:00 PM | AFTERNOON WORKSHOP

Neck Anatomy for HA Injectors LIVE DEMO	Robyn Siperstein, MD	General Session Room
--	----------------------	----------------------

4:00 – 4:15 PM | COFFEE BREAK

Mediterranean Foyer

4:15 – 6:00 PM | AFTERNOON WORKSHOPS – CONCURRENT

4:15 – 5:00 PM Flaps and Grafts: Improving Cosmetic Results and Healing Outcomes	Timothy Flynn, MD, and Joel Cohen, MD	General Session Room
4:15 – 5:00 PM Pediatric Derm Emergencies	Kalyani Marathe, MD	Mediterranean 6
5:00 – 6:00 PM Dermoscopy for the Practicing Dermatologist	Jennifer Stein, MD	General Session Room

6:00 – 7:00 PM | DINNER SYMPOSIUM (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

Top Cosmeceutical Picks from La Roche-Posay for Restorative and Preventative Aging PRODUCT DISTRIBUTION Supported by La Roche-Posay	Timothy Flynn, MD Nada Elbuluk, MD	Mediterranean 6
---	--------------------------------------	-----------------

AGENDA | FRIDAY, JANUARY 13, 2023

8:00 – 9:00 AM | BREAKFAST WORKSHOPS (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

Alopecia Areata: What You Need to Know Supported by Pfizer	Amy McMichael, MD	Mediterranean 6
VTAMA® (tapinarof) cream, 1% as a Novel Topical Therapy for Adult Plaque Psoriasis Supported by Dermavant	George Han, MD	Mediterranean 7

9:00 – 11:00 AM | GENERAL SESSION I – AESTHETIC AND MEDICAL DERMATOLOGY TOPICS

Welcome and Introductions	Adam Friedman, MD	General Session Room
Scarring Alopecias: How to Arrest Loss and Promote Regrowth	Amy McMichael, MD	General Session Room
Challenging Cases of Hidradenitis Suppurativa – Expert Panel	Moderator: Adam Friedman, MD Faculty: Hadar Lev-Tov, MD, Iltefat Hamzavi, MD	General Session Room
Breaking the Cycle: Unconscious Bias and Microaggressions in Dermatology	Omar Qutub, MD, Adam Friedman, MD, Nada Elbuluk, MD	General Session Room
My Top Pearls for Leading Culturally Competent Cosmetic Consults	Kavita Mariwalla, MD	General Session Room
Walk Me Through It: Using Lasers and Energy-Based Devices to Treat Redness and Facial Vessels	Ariza Ortiz, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience		General Session Room

11:00 – 11:30 AM | COFFEE BREAK

Mediterranean Foyer

AGENDA | FRIDAY, JANUARY 13, 2023 – CONTINUED

11:00 AM – 12:30 PM | MORNING WORKSHOPS

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

11:00 AM – 12:30 PM Aesthetic Dermatology Workshop – Part I FOCUS: Upper Face and Mid Face LIVE DEMOS	Kavita Mariwalla, MD, Nazanin Saedi, MD	General Session Room
11:30 AM – 12:30 PM How Would You Reconstruct It?	C. William Hanke, MD, Timothy Flynn, MD	Palazzo ABC
11:30 AM – 12:30 PM Setting Up Shop: Different Ways of Building a Practice – Expert Panel	Omar Qutub, MD, Robyn Siperstein, MD	Mediterranean 8

12:30 – 1:45 PM | LUNCH BREAK IN THE EXHIBIT HALL

12:30 – 1:30 PM | LUNCH WORKSHOPS (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

A Treatment Option for Adults with Prurigo Nodularis <i>Supported by Sanofi and Regeneron Pharmaceuticals, Inc.</i>	Adam Friedman, MD	Mediterranean 6
Mild to Moderate Atopic Dermatitis: Burden of Disease and a Topical Pathway for JAK Inhibition <i>Supported by Incyte</i>	Leon Kircik, MD	Mediterranean 7

1:45 – 3:45 PM | GENERAL SESSION II – AESTHETIC AND MEDICAL DERMATOLOGY TOPICS

Welcome and Introductions	Susan Weinkle, MD	General Session Room
USA Regulatory Scrutiny of Regenerative Medicine and PRP: Medicolegal Implications	Terrence Keaney, MD	General Session Room
Walk Me Through It: Using Lasers and Energy-Based Devices to Treat Acne Scars – Case-Based Panel	DiAnne Davis, MD, Ariza Ortiz, MD	General Session Room
What Your Dermatopathologist Wishes You Knew	Molly Hinshaw, MD	General Session Room
What's New in Wound Healing	Hadar Lev-Tov, MD	General Session Room
What's New in Pediatric Inflammatory Skin Conditions	A. Yasmine Kirkorian, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

1:45 – 3:45 PM | RESIDENT AND YOUNG DERM FOCUSED TRACK | Concurrent to General Session

Welcome and Introductions	Adam Friedman, MD	Palazzo ABC
Becoming Involved in Clinical Trials and Working with Industry	Moderator: Joel Cohen, MD Faculty: Blair Allais, MD, Leon Kircik, MD, Kavita Mariwalla, MD, Adam Friedman, MD	Palazzo ABC
Career Panel Open Forum with ODAC Faculty	Moderator: Adam Friedman, MD Faculty: Blair Allais, MD, Kalyani Marathe, MD, DiAnne Davis, MD, Terrence Keaney, MD	Palazzo ABC
Behind the Podium: Best Practices for Developing Impactful Lectures and Making it into the Conference Circuit	Adam Friedman, MD, George Han, MD	Palazzo ABC

3:45 – 4:30 PM | COFFEE BREAK IN THE EXHIBIT HALL

Coffee Chat with Faculty	Molly Hinshaw, MD, C. William Hanke, MD	Exhibit Hall
Meet and Greet with Poster Presenters		Mediterranean 1-3 Foyer

4:30 – 6:30 PM | GENERAL SESSION III – MEDICAL AND AESTHETIC DERMATOLOGY TOPICS FEATURING LIVE DEMONSTRATIONS

Welcome and Introductions	James Spencer, MD	General Session Room
Acne: Where Are We With....	Adam Friedman, MD	General Session Room
What On Earth Is That? - Interactive Case-Based Challenge - Peds Edition!	Kalyani Marathe, MD, A. Yasmine Kirkorian, MD	General Session Room

Walk Me Through It: Using Lasers to Treat Fine Lines and Rhytids – Case-Based Panel	Joel Cohen, MD, Mathew Avram, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room
Live Injectables Demonstrations: Facial Assessment & Full Face Rejuvenation LIVE DEMOS	Susan Weinkle, MD, Joel Cohen, MD	General Session Room

6:30 – 7:00 PM | KEYNOTE ADDRESS

Humanae: The Beauty of Being Human	Angélica Dass	General Session Room
------------------------------------	---------------	----------------------

7:00 – 8:30 PM | WELCOME RECEPTION IN THE EXHIBIT HALL

AGENDA | SATURDAY, JANUARY 14, 2023

7:20 – 8:20 AM | BREAKFAST WORKSHOPS (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

WINLEVI® (clascoterone) cream 1%, First-in-Class Topical Androgen Receptor Inhibitor for the Treatment of Acne Vulgaris <i>Supported by Sun Pharmaceuticals</i>	Leon Kircik, MD	Mediterranean 6
--	-----------------	-----------------

8:30 – 10:30 AM | GENERAL SESSION I

Welcome and Introductions	James Spencer, MD	General Session Room
Common Dermatologic Diseases Uncommonly Talked About	Adam Friedman, MD	General Session Room
An Update on Nail Disorders and Their Management	Molly Hinshaw, MD	General Session Room
Personalized Medicine for Atopic Dermatitis: Picking the Right Treatment for the Right Patient - Expert Panel	Adam Friedman, MD, Shawn Kwatra, MD	General Session Room
What's in Your Vial? - An in Depth Look at the Active and Inactive Ingredients in the FDA Approved Neuromodulators	Terrence Keaney, MD	General Session Room
Heavy Ablative Resurfacing: Dr. Cohen's Protocol	Joel Cohen, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

10:30 – 11:00 AM | COFFEE BREAK IN THE EXHIBIT HALL

Coffee Chat with Faculty	Omar Ibrahimi, MD, Nazanin Saedi, MD	Exhibit Hall
--------------------------	--------------------------------------	--------------

10:30 – 11:00 AM | MORNING WORKSHOP - CONCURRENT TO COFFEE BREAK

Entrepreneurship in Dermatology	John Harris, MD	Mediterranean 8
---------------------------------	-----------------	-----------------

11:00 AM – 12:30 PM | GENERAL SESSION II

Welcome and Introductions	C. William Hanke, MD	General Session Room
Live Injectables Demonstrations - Upper Face LIVE DEMOS	Susan Weinkle, MD, Robyn Siperstein, MD	General Session Room
Filler Necrosis: Understanding, Avoiding and Managing Complications	Joel Cohen, MD	General Session Room
Pragmatic Pearls on Rosacea Pathophysiology and Practice	Adam Friedman, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

12:30 – 1:30 PM | LUNCH BREAK IN THE EXHIBIT HALL

AGENDA | SATURDAY, JANUARY 14, 2023 – CONTINUED

12:30 – 1:30 PM | LUNCH WORKSHOP (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

Insights Into a New Oral Treatment Option for Adults With Moderate-to-Severe Plaque Psoriasis <i>Supported by Bristol Myers Squibb</i>	Adam Friedman, MD	Mediterranean 6
A Targeted Approach to the Treatment of Nonsegmental Vitiligo <i>Supported by Incyte</i>	Heather Woolery-Lloyd, MD	Mediterranean 7

1:30 – 3:30 PM | GENERAL SESSION III

Welcome and Introductions	Joel Cohen, MD	General Session Room
Live Injectables Demonstrations - Mid Face	Susan Weinkle, MD, John Fezza, MD	General Session Room
The Medicine Chest: What's New and What's Coming - Part 1	Leon Kircik, MD	General Session Room
Melanoma Detection Update	Jennifer Stein, MD	General Session Room
If You Pain Them, You Won't Retain Them: Pain Mitigation Strategies from the Experts	Terrence Keaney, MD, Joel Cohen, MD, James Spencer, MD, Susan Weinkle, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

3:30 – 4:30 PM | COFFEE BREAK IN THE EXHIBIT HALL

3:30 – 4:30 PM | AFTERNOON WORKSHOP (Non-CE)

AART of GAIN LIVE DEMOS <i>Supported by Galderma</i>	Robyn Siperstein, MD, Joel Cohen, MD	Mediterranean 6
--	--------------------------------------	-----------------

4:30 – 5:30 PM | AFTERNOON WORKSHOPS - CONCURRENT

Dealing with Red Flag Patients: This Is How the Experts Do It	Moderator: Omar Qutub, MD Faculty: Adam Friedman, MD, A. Yasmine Kirkorian, MD, Omar Ibrahimi, MD	Palazzo ABC
Taking Your Dermoscopy Skills to the Next Level	Jennifer Stein, MD	Mediterranean 8
Aesthetic Derm Workshop - Part II - Focus: Lower Face HANDS ON <i>All attendees are welcome to observe, however, the hand-on portion is available only to residents.</i>	Kavita Mariwalla, MD, Nazanin Saedi, MD	General Session Room

5:30 – 6:30 PM | DINNER SYMPOSIUMS (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

Make SILIQ Your Bio-Logical Next Step <i>Supported by Ortho Dermatologics</i>	George Han, MD	Mediterranean 6
Join Pfizer: Learn About an Oral RX Treatment for Moderate-to-Severe Atopic Dermatitis <i>Supported by Pfizer</i>	Zakiya Rice, MD	Mediterranean 7

AGENDA | SUNDAY, JANUARY 15, 2023

7:20 – 8:20 AM | BREAKFAST WORKSHOPS (Non-CE)

Seats are limited and available on a first come, first-served basis. Please plan to arrive early.

SP Dynamis, The Best Multi-Use Energy Device LIVE DEMOS <i>Supported by Fotona</i>	DiAnne Davis, MD	Mediterranean 6
--	------------------	-----------------

8:30 – 10:30 AM | GENERAL SESSION I

Welcome and Introductions	C. William Hanke, MD	General Session Room
---------------------------	----------------------	----------------------

AGENDA | SUNDAY, JANUARY 15, 2023 – CONTINUED

Live Injectables Demonstrations LIVE DEMOS	Nazanin Saedi, MD, Kavita Mariwalla, MD	General Session Room
Procedural Complications: An Algorithmic Approach to Management	David Ozog, MD	General Session Room
Gene Expression Profiling (GEP): Where Do We Stand	Vishal A. Patel, MD	General Session Room
The Medicine Chest: What's New and What's Coming - Part 2	Leon Kircik, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

10:30 – 11:00 AM | COFFEE BREAK IN THE EXHIBIT hall

Coffee Chat with Faculty	DiAnne Davis, MD, Shawn Kwatra, MD
--------------------------	------------------------------------

10:30 – 11:00 AM | MORNING WORKING GROUP - CONCURRENT TO COFFEE BREAK

Non-Surgical Treatment of Skin Cancers	Vishal Patel, MD	Mediterranean 8
Medico-Legal Issues in Procedural Dermatology	Mathew Avram, MD	Mediterranean 7

11:00 AM – 12:30 PM | GENERAL SESSION II

Welcome and Introductions	Omar Qutub, MD	General Session Room
What On Earth Is That? - Interactive Case-Based Challenge	Adam Friedman, MD, George Han, MD	General Session Room
Psoriasis: Topical, Oral, and Photo Therapies	George Han, MD	General Session Room
Walk Me Through It: Using Lasers and Energy-Based Devices to Treat Surgical and Trauma Scars - Case-Based Panel	David Ozog, MD, Mathew Avram, MD, Joel Cohen, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

12:30 – 1:45 PM | LUNCH BREAK IN THE EXHIBIT HALL

1:45 – 3:45 PM | GENERAL SESSION III

Welcome and Introductions	Adam Friedman, MD	General Session Room
Treatment of Infraorbital Hollows - Expert Panel	Robyn Siperstein, MD, John Fezza, MD	General Session Room
Walk Me Through It: Using Lasers to Treat Facial Pigmentation and Lentigines - Case-Based	Omar Ibrahimi, MD	General Session Room
New Findings and Emerging Therapies for Blistering Disorders	Kaarl Saardi, MD	General Session Room
Racial Disparities in Itch: From Bench to Bedside	Shawn Kwatra, MD	General Session Room
Treatment Approaches for Alopecias - Case-Based Expert Panel	Amy McMichael, MD, DiAnne Davis, MD, Adam Friedman, MD	General Session Room
Ask Me Anything! Faculty Q&A with the Audience	All Faculty	General Session Room

3:45 – 4:00 PM | COFFEE BREAK

4:00 – 5:45 PM | AFTERNOON WORKSHOPS

4:00 - 5:15 PM Aesthetic Derm Workshop - Part III Full Face Rejuvenation	Kavita Mariwalla, MD, Nazanin Saedi, MD	General Session Room
4:00 - 4:45 PM Managing the Itchy patient: Updates on Pathogenesis and Management	Shawn Kwatra, MD	Mediterranean 6
4:45 - 5:45 PM Trichoscopy Clues for Diagnosing Common Hair Disorders	Amy McMichael, MD	Mediterranean 7

CONFERENCE CONCLUDES



**TAKE A
NEW LOOK**

VISIT INCYTE AT BOOTH 209

Incyte and the Incyte logo are registered trademarks of Incyte.
© 2022, Incyte Corporation. MAT-DRM-00840 12/22

ACCREDITATION STATEMENT

PROGRAM OVERVIEW AND STATEMENT OF NEED

The field of dermatology is constantly evolving. Physicians and medical professionals must keep current on emerging dermatological issues, techniques, and treatment skills in order to safely and effectively meet their patients' needs. ODAC delivers a comprehensive and compelling look at the practice of dermatology with a strong focus on timely issues affecting dermatological practice. ODAC provides attendees with an understanding of the evolution of both clinical and aesthetic dermatology as a medical and surgical discipline.

EDUCATIONAL METHOD

The ODAC conference consists of didactic lecture presentations, case-study review, case-based learning in small groups, simulation-based medical education, live demonstrations and hands-on live patient injections. The ODAC program also has several question and answer opportunities including the use of real-time, interactive audience response systems.

INTENDED AUDIENCE

The intended audience for this symposium includes dermatologists, dermatology residents, fellows and young practitioners, dermatology nurse practitioners and physician assistants, and other physicians with an interest in management of cutaneous diseases, disorders and the aesthetic treatment of patients of all ages and skin types.

LEARNING OBJECTIVES

Upon completion of the ODAC, participants should be able to:

- Define intrinsic and extrinsic factors of the normal aging process in patients with all skin types
- Select and formulate the appropriate aesthetic treatment plan using neurotoxins, dermal fillers, laser and light-based energy therapy technologies and cosmeceutical products in patients of all skin types who seek improvement in facial and skin appearance
- Compare patient selection, choice of injectable products and technique required to avoid potential complications and achieve optimal patient outcomes
- Express current understanding of the pathophysiology of acne as it relates to effective diagnosis and treatment
- Discuss current theories on the pathogenesis of rosacea including the identification of genetic factors and gene loci that predispose affected patients to a rosacea phenotype
- Analyze evidence-based data on acne treatment options in order to improve treatment outcomes and improve patient adherence to therapy
- Examine emerging clinical and therapeutic science insights into the pathogenesis and effective management of atopic dermatitis including new modalities recently introduced into clinical practice
- Discuss the role of the innate and adaptive immune system function in normal skin and how changes in the immune system may contribute to inflammatory disease
- Identify the psoriasis patient population that would benefit most from topical and systemic therapies including biologic response modifiers
- Assess evidence-based data on the relationship between psoriasis comorbidities and therapeutic selection

- Indicate the types of superficial fungal infection presenting in the dermatology setting including tinea pedis, tinea cruris and tinea corporis and onychomycosis and formulate effective treatment strategies
- Summarize current and emerging therapies that hold promise for the effective treatment of skin cancers including actinic keratosis, basal cell carcinoma and melanoma
- Identify the impact of various cutaneous disorders affecting the delivery of quality dermatologic care including seborrheic keratosis and other non-cancerous growths, chronic urticaria, hyperhidrosis among others
- Recognize the impact of race, ethnicity and cultural practices on the treatment of cutaneous diseases in persons with diverse skin types
- Differentiate clinical signs of disorders of pigmentation including melasma and vitiligo and outline treatment courses effective for patients of all skin types

PHYSICIAN CONTINUING MEDICAL EDUCATION – AMA (MDS, DOS)

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 27.5 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING PA EDUCATION – AAPA

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 27.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation.

CONTINUING NURSING EDUCATION – ANCC (RNS, APRNS, NPS)

The maximum number of hours awarded for this Continuing Nursing Education activity is 27.5 contact hours. Nurses should claim only credit commensurate with the extent of their participation in the activity.

JOINT ACCREDITATION STATEMENT



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Physicians' Continuing Education Corporation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

*This live continuing education activity for US dermatology healthcare providers is supported by independent medical education grants provided by: Galderma Laboratories, L.P.

*In-kind support has been provided by: Galderma Laboratories, L.P., Merz North America, Inc., Revance Therapeutics Inc.

*As of 1/3/23

Jointly Provided By



Postgraduate Institute
for Medicine



ONCE-DAILY

CIBINQO[™]
(abrocitinib) tablets | 50mg
100mg
200mg

Product Theater
(Non-CME)
Sponsored by
Pfizer Inc.

Learn More About CIBINQO[™] (abrocitinib)

Join us for a Pfizer-sponsored presentation of CIBINQO, a once-daily, oral JAK inhibitor for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Saturday, January 14, 2023

5:30 PM to 6:30 PM EST

JW Marriott Grande Lakes
Mediterranean 7



Zakiya P. Rice, MD

Pfizer Inc invites you to one of its expert therapeutic update sessions for CIBINQO. During this program, an atopic dermatitis expert will discuss the efficacy and safety profile of CIBINQO and will showcase a hypothetical profile, elucidating which of your patient types may be appropriate for this treatment option.

This promotional activity is offered by Pfizer and does not include any continuing education credits. The content of the Expert Therapeutic Update and opinions expressed by speakers are those of the company and/or speakers and not of the Orlando Dermatology Aesthetic & Surgical Conference. Speakers present on behalf of the supporting company and together are responsible for providing information in compliance with FDA regulations.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS

SERIOUS INFECTIONS

Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death. The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia.

If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.

Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions:

- Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.
- Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

Avoid use of CIBINQO in patients with an active, serious infection, including localized infections. The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections or those who have resided or traveled in areas of endemic tuberculosis or endemic mycoses.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO.

Please see additional Important Safety Information on back cover, and full Prescribing Information, including **BOXED WARNING**, and Medication Guide inside pocket.



IMPORTANT SAFETY INFORMATION (CONTINUED) AND INDICATION

SERIOUS INFECTIONS (Continued)

Viral reactivation, including herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO™ (abrocitinib). If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves. Hepatitis B virus reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C.

MORTALITY

In a large, randomized postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality (including sudden cardiovascular death) was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.

MALIGNANCIES

Malignancies, including non-melanoma skin cancer (NMSC), were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

In a large, randomized postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. CIBINQO is not approved for use in RA patients. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

THROMBOSIS

Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of overall thrombosis, DVT, and PE were observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients.

Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and treat patients appropriately.

CONTRAINDICATION

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤ 81 mg daily), during the first 3 months of treatment.

LABORATORY ABNORMALITIES

Hematologic Abnormalities: Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia. Prior to CIBINQO initiation, perform a complete blood count (CBC). CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities.

Lipid Elevations: Dose dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy, and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.

IMMUNIZATIONS

Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including prophylactic herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.

RENAL IMPAIRMENT

Avoid use in patients with severe renal impairment or end stage renal disease, including those on renal replacement therapy.

HEPATIC IMPAIRMENT

Avoid use in patients with severe hepatic impairment.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 1\%$) in subjects receiving 100 mg and 200 mg include: nasopharyngitis, nausea, headache, herpes simplex, increased blood creatinine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, gastroenteritis.

Most common adverse reactions ($\geq 1\%$) in subjects receiving either 100 mg or 200 mg also include: impetigo, hypertension, contact dermatitis, upper abdominal pain, abdominal discomfort, herpes zoster, and thrombocytopenia.

Inform patients that retinal detachment has been reported in CIBINQO clinical trials. Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision.

DRUG INTERACTIONS

Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. See Prescribing Information for clinically relevant drug interactions.

USE IN PREGNANCY

Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise females of reproductive potential that CIBINQO may impair fertility.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770.

LACTATION

Advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose.

INDICATION

CIBINQO is indicated for the treatment of adults with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Please see additional Important Safety Information on front cover, and full Prescribing Information, including **BOXED WARNING**, and Medication Guide inside pocket.



THANK YOU TO OUR 2023 SUPPORTERS AND EXHIBITORS

PLATINUM SUPPORTERS



GOLD SUPPORTERS



SILVER SUPPORTER



SUPPORT LEVEL

